We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Review · April 19, 2021

Sapanisertib + Exemestane or Fulvestrant for HR-Positive/HER2-Negative Advanced/Metastatic Breast Cancer

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Sapanisertib Plus Exemestane or Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Clin. Cancer Res 2021 Apr 05;[EPub Ahead of Print], B Lim, DA Potter, MA Salkeni, P Silverman, TC Haddad, F Forget, A Awada, JL Canon, M Danso, A Lortholary, H Bourgeois, E Tan-Chiu, S Vincent, B Bahamon, KJ Galinsky, C Patel, R Neuwirth, EJ Leonard, JR Diamond

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading